FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg £68
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  3. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  4. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  5. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  6. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  7. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  8. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  9. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  10. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  11. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  12. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  13. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  14. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  15. He R, et al. 2021. J Immunol. 206:2353. PubMed
  16. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  17. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  18. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  19. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  20. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  21. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  22. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  23. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  24. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  27. Toomer G, et al. 2022. Viruses. 14:. PubMed
  28. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  29. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  30. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  31. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  32. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  33. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  34. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  35. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  36. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  37. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  38. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  39. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  40. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  41. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  42. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  43. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  44. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  45. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  46. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  47. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  48. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  49. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  50. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  51. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  52. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  53. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  54. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  55. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  56. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  57. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  58. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  59. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  60. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  61. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  62. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  63. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  64. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  65. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  66. White C, et al. 2014. J Immunol. 193:5933. PubMed
  67. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  68. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  69. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  70. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  71. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  72. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  73. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  74. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  75. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  76. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  77. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  78. He X, et al. 2021. Small. 17:e2007165. PubMed
  79. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  80. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  81. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  82. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  83. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  84. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  85. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  86. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  87. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  88. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  89. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  90. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  91. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  92. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  93. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  94. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  95. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  96. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  97. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  98. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  99. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  100. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  101. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  102. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  103. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  104. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  105. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  106. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  107. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  108. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  109. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  110. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  111. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  112. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  113. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  114. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  115. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  116. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  117. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  118. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  119. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  120. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  121. Lang V, et al. 2021. Elife. 10:. PubMed
  122. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  123. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  124. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  125. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  126. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  127. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  128. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  129. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  130. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  131. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  132. Ma K, et al. 2022. iScience. 25:104347. PubMed
  133. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  134. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  135. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  136. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  137. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  138. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  139. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  140. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  141. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  142. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  143. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  144. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  145. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  146. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  147. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  148. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  149. Li J, et al. 2020. Development. :. PubMed
  150. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  151. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  152. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  153. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  154. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  155. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  156. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  157. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  158. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  159. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  160. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  161. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  162. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  163. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  164. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  165. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  166. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  167. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  168. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  169. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  170. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  171. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  172. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  173. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  174. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  175. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  176. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  177. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  178. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  179. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  180. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  181. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  182. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  183. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  184. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  185. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  186. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  187. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  188. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  189. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  190. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  191. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  192. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  193. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  194. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  195. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  196. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  197. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  198. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  199. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  200. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  201. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  202. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  203. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  204. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  205. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  206. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  207. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  208. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  209. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  210. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  211. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  212. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  213. Gawish R, et al. 2022. Elife. 11:. PubMed
  214. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  215. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  216. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  217. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  218. Zeng A, et al. 2020. Oncol Rep. . PubMed
  219. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  220. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  221. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  222. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  223. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  224. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  225. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  226. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  227. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  228. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  229. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  230. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312691 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account